Comments
Alembic Pharmaceuticals has received the US health regulator’s approval to market hypertension drug, Candesartan Cilexetil tablets, in the American market.
The company’s product is therapeutically equivalent to AstraZeneca Pharmaceuticals’ Atacand tablets which are indicated for treatment of hypertension, Alembic today said in a regulatory filing.
According to IMS data, Candesartan Cilexetil tablets had an estimated market size of $27 million in the US market for the 12 months ended December 2016.
Alembic now has a total of 57 abbreviated new drug application (ANDA) approvals from the USFDA.
Shares of the company today closed 2.28 per cent higher at Rs 534.90 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.